About: Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 December 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 2007 (uk) article scientifique publié en 2007 (fr) im Dezember 2007 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'avientu de 2007 (ast) scientific article published on 01 December 2007 (en)
publication date	wds:Q58971166-F30084EF-CB95-4DBD-BA44-2E054EA0B9A1
publication date	2007-12-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q58971166-120FA1BE-9782-4290-8F19-7617076AA390 wds:Q58971166-565C3EEE-1F44-41E9-B081-44EFE2C71639
cites work	Role of RANK ligand in mediating increased bone resorption in early postmenopausal women Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
author name string	wds:Q58971166-19593B72-2666-4E53-8C1E-9CE7529B89E2 wds:Q58971166-197B1F44-41A5-48AF-80DC-4E8DD5AEFEF2 wds:Q58971166-3C90977B-C198-4C33-B607-0AFDF6CA5FB5 wds:Q58971166-49D5600A-8463-4861-94A9-AF76DE24BD20 wds:Q58971166-4D7802D2-8F4E-4CF6-A1AB-95B82D408C10 wds:Q58971166-600D9E82-4B78-4E42-A311-FEEC2460EAC4 wds:Q58971166-BED4FE84-5C84-4BED-A1AA-BD7337B689C4 wds:Q58971166-D22A71A8-5212-4D9D-924A-37EED71424FD
author name string	Yu Liu Lorraine A Fitzpatrick E Michael Lewiecki Andrea Wang Paul D Miller Michael A Bolognese Suresh Siddhanti AMG 162 Bone Loss Study Group
rdfs:label	Two-Year Treatment With Denosumab (nl) Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD (en)
skos:prefLabel	Two-Year Treatment With Denosumab (nl) Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD (en)
name	Two-Year Treatment With Denosumab (nl) Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD (en)
author	wds:Q58971166-54BF1AF4-C455-4306-BB4B-7AD294E643D7 wds:Q58971166-9ABDDB66-0D92-46C1-AABA-F4BABFE2A90C
author	Stanley B Cohen Michael McClung
title	wds:Q58971166-C138BFB6-B480-4150-A5B4-BD478B6DDFEB
title	Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD (en)
page(s)	wds:Q58971166-E2B50FD4-ACBB-4BBB-BC6C-681DB1767D2E
page(s)	1832-1841
instance of	wds:Q58971166-4ADB9BD4-1592-471F-8A35-8EE78B15F059
instance of	scholarly article
PubMed ID	wds:Q58971166-C42A0650-F860-448C-8C0B-B66CE8FB999C
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17708711
PubMed ID	17708711
published in	wds:Q58971166-35AED73F-D2AF-4A6D-8FD2-B9175E8A6055
published in	Journal of Bone and Mineral Research
issue	wds:Q58971166-80F1B480-05FA-46B7-9B9F-E72421A37B07
volume	wds:Q58971166-4B3D2807-3B12-4BC0-87BE-401B57B4833C
issue	12
volume	22
DOI	wds:Q58971166-C51946AB-5803-4B4C-B293-8167E4E12E2D
DOI	http://dx.doi.org/10.1359/JBMR.070809
DOI	10.1359/JBMR.070809
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58971166
is cites work of	Denosumab: anti-RANKL antibody Chemerin neutralization blocks hematopoietic stem cell osteoclastogenesis Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis Osteoporosis: now and the future Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab. Functions of RANKL/RANK/OPG in bone modeling and remodeling Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Current options for the management of postmenopausal osteoporosis Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis A review of denosumab for the treatment of osteoporosis Regulatory mechanisms of RANKL presentation to osteoclast precursors Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. RANKL/RANK-beyond bones An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial Data from extension trials: denosumab and zoledronic acid Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Potential new drug targets for osteoporosis Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis Denosumab for the treatment of osteoporosis and cancer-related conditions Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women Bone physiology, disease and treatment: towards disease system analysis in osteoporosis Antibody to receptor activator of NF-κB ligand ameliorates T cell-mediated periodontal bone resorption Denosumab: a review of its use in the treatment of postmenopausal osteoporosis Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications Porphyromonas gingivalis infection-associated periodontal bone resorption is dependent on receptor activator of NF-κB ligand Age-dependence of femoral strength in white women and men. Current, new and future treatments of osteoporosis Denosumab The clinical use of denosumab for the management of low bone mineral density in postmenopausal women Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT) Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer Current and future treatment options in osteoporosis Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software